• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Reva Medical wins CE Mark for Fantom bioresorbable scaffold

April 4, 2017 By Sarah Faulkner

Reva Medical wins CE Mark for Fantom bioresorbable scaffoldReva Medical (ASX:RVA) said yesterday that it won CE Mark approval in the European Union for its Fantom sirolimus-eluting bioresorbable coronary scaffold.

The Fantom scaffold is the San Diego, Calif.-based company’s 1st commercial product. Reva said it plans to begin selling the product in Europe this quarter.

“CE Mark approval for Fantom is a major milestone for the company. It is the culmination of years of effort,” CEO Reggie Groves said in prepared remarks. “As the patient population becomes increasingly acquainted with the appeal of bioresorbable scaffolds in general, versus metal stents, we believe they will come to ask for Fantom by name, based on our positive data and the increasing preference for Fantom that we expect leading clinicians will develop over time.”

Data from the company’s Fantom II 240-patient trial were used to support the CE Mark application, Reva said. The study’s major adverse cardiac event rate through 6 months was 2.1%, which compared favorably to commercial 1st-gen bioresorbable scaffolds, according to Reva. The company said it plans to publish additional data in May and October this year.

Reva is also pursuing private funding to support the commercial launch of Fantom, as well as its ongoing needs, including clinical trials and new product feasibility work. The company said it expects its financing to close before the end of this month.

Reva is just the latest entrant into the European biodegradable coronary stent market, joining Abbott (NYSE:ABT), Biotronik and Elixir Medical.

Abbott won CE Mark approval for its Absorb stent in 2011 and 3 years later, Elixir was granted European regulatory approval for its fully-bioresorbable coronary scaffold, DESolve. Biotronik won CE Mark approval for its Magmaris stent last year.

Abbott’s fully-biodegradable Absorb stent won FDA approval in July last year, making it the 1st fully-dissolving stent commercially available in the U.S. for the treatment of coronary artery disease.

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Regulatory/Compliance, Vascular, Wall Street Beat Tagged With: Abbott Laboratories, Biotronik, Elixir Medical Corporation, Reva Medical

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS